Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of March PADAC Meeting

Related THRX
Theravance Inc Reports Prelim Tender Offer Results
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan

Stifel Nicolaus maintained Theravance (NASDAQ: THRX) with a Buy rating and lowered the price target from $40.00 to $37.00.

Stifel Nicolaus commented, "We expect the release of BREO briefing docs (likely March 4th/5th) and subsequent PADAC meeting to likely generate a meaningful amount of volatility in the stock. However, we continue to like the risk/reward at current levels and remain Buy-rated with $37 target price."

Theravance closed at $21.60 on Tuesday.

Latest Ratings for THRX

May 2015Cowen & Co.DowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014StifelDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings


Related Articles (THRX)

View Comments and Join the Discussion!